Literature DB >> 23252704

High-resolution melting analysis of the TPMT gene: a study in the Polish population.

Marzena Skrzypczak-Zielinska1, Pawel Borun, Katarzyna Milanowska, Ludwika Jakubowska-Burek, Oliwia Zakerska, Agnieszka Dobrowolska-Zachwieja, Andrzej Plawski, Ursula G Froster, Marlena Szalata, Ryszard Slomski.   

Abstract

The thiopurine S-methyltransferase (TPMT) gene encoding thiopurine methyltransferase is a crucial enzyme in metabolism of thiopurine drugs: azathioprine and 6-mercoptopurine, which are used in the treatment of leukemia or inflammatory bowel diseases. Genetic polymorphism of the TPMT gene correlates with activity of this enzyme, individual reaction, and dosing of thiopurines. Thirty-one variants of the TPMT gene with low enzymatic activity have been described with three major alleles: TPMT*2 (c.238G>C), *3A (c.460 G>A, c.719A>G), and *3C (c.719A>G), accounting for 80% to 95% of inherited TPMT deficiency in different populations in the world. The aim of the study was to establish a rapid and highly sensitive method of analysis for the complete coding sequence of the TPMT gene and to determine the spectrum and prevalence of the TPMT gene sequence variations in the Polish population. Recently, high-resolution melting analysis (HRMA) has become a highly sensitive, automated, and economical technique for mutation screening or genotyping. We applied HRMA for the first time to TPMT gene scanning. In total, we analyzed 548 alleles of the Polish population. We found 11 different sequence variations, where two are novel changes: c.200T>C (p.P67S, TPMT*30) and c.595G>A (p.V199I, TPMT*31). Detection of these new rare alleles TPMT*30 and *31 in the Polish population suggests the need to analyze the whole TPMT gene and maybe also the extension of routinely used tests containing three major alleles, TPMT*2, *3A, and *3C. Identification of sequence variants using HRMA is highly sensitive and less time consuming compared to standard sequencing. We conclude that HRMA can be easy integrated into genetic testing of the TPMT gene in patients treated with thiopurines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23252704      PMCID: PMC3552168          DOI: 10.1089/gtmb.2012.0192

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  32 in total

1.  Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients.

Authors:  B Pandya; W Thomson; K Poulton; I Bruce; D Payne; F Qasim
Journal:  Transplant Proc       Date:  2002-08       Impact factor: 1.066

2.  Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals.

Authors:  H L McLeod; S C Pritchard; J Githang'a; A Indalo; M M Ameyaw; R H Powrie; L Booth; E S Collie-Duguid
Journal:  Pharmacogenetics       Date:  1999-12

3.  High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC.

Authors:  E Schaeffeler; T Lang; U M Zanger; M Eichelbaum; M Schwab
Journal:  Clin Chem       Date:  2001-03       Impact factor: 8.327

4.  Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects.

Authors:  A M Rossi; M Bianchi; C Guarnieri; R Barale; G M Pacifici
Journal:  Eur J Clin Pharmacol       Date:  2001-04       Impact factor: 2.953

5.  Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase.

Authors:  R Weinshilboum
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

6.  Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, "two-color/shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design.

Authors:  E Schütz; N von Ahsen; M Oellerich
Journal:  Clin Chem       Date:  2000-11       Impact factor: 8.327

7.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity.

Authors:  Malin Lindqvist; Sofie Haglund; Sven Almer; Curt Peterson; Jan Taipalensu; Erik Hertervig; Ebbe Lyrenäs; Peter Söderkvist
Journal:  Pharmacogenetics       Date:  2004-04

8.  Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis.

Authors:  Carlynn Willmore; Joseph A Holden; Luming Zhou; Sheryl Tripp; Carl T Wittwer; Lester J Layfield
Journal:  Am J Clin Pathol       Date:  2004-08       Impact factor: 2.493

9.  Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease.

Authors:  Sofie Haglund; Malin Lindqvist; Sven Almer; Curt Peterson; Jan Taipalensuu
Journal:  Clin Chem       Date:  2003-12-04       Impact factor: 8.327

10.  A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations.

Authors:  Rebecca L Roberts; Murray L Barclay; Richard B Gearry; Martin A Kennedy
Journal:  Clin Chim Acta       Date:  2004-03       Impact factor: 3.786

View more
  3 in total

1.  High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype.

Authors:  Yoichi Kakuta; Yasuhiro Izumiyama; Daisuke Okamoto; Takeru Nakano; Ryo Ichikawa; Takeo Naito; Rintaro Moroi; Masatake Kuroha; Yoshitake Kanazawa; Tomoya Kimura; Hisashi Shiga; Hisaaki Kudo; Naoko Minegishi; Yosuke Kawai; Katsushi Tokunaga; Masao Nagasaki; Yoshitaka Kinouchi; Yasuo Suzuki; Atsushi Masasmune
Journal:  J Gastroenterol       Date:  2019-10-22       Impact factor: 7.527

Review 2.  Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.

Authors:  Chingiz Asadov; Gunay Aliyeva; Kamala Mustafayeva
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2017-11-08

3.  A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.

Authors:  Marzena Skrzypczak-Zielinska; Pawel Borun; Anna Bartkowiak-Kaczmarek; Oliwia Zakerska-Banaszak; Michal Walczak; Agnieszka Dobrowolska; Mateusz Kurzawski; Malgorzata Waszak; Daniel Lipinski; Andrzej Plawski; Ryszard Slomski
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.